Exosomes, Extracellular Vesicles A Technology Review ... Exosomes, Extracellular Vesicles: Topic Introduction

  • View
    12

  • Download
    0

Embed Size (px)

Text of Exosomes, Extracellular Vesicles A Technology Review ... Exosomes, Extracellular Vesicles: Topic...

  • Exosomes, Extracellular Vesicles A Technology Review

    1

  • Author, Data Collection Date, Notes

    •  The Author –  Gary M. Oosta, holds a Ph.D. in Biophysics from Massachusetts Institute of Technology and a B.A. in Chemistry from E.

    Mich. Univ. He has 25 years of industrial research experience in various technology areas including medical diagnostics, thin-layer coating, bio-effects of electromagnetic radiation, and blood coagulation. Dr. Oosta has authored more than 20 technical publications and is an inventor on 77 patents worldwide. In addition, he has managed research groups that were responsible for many other patented innovations. Dr. Oosta has a long-standing interest in using patents and publications as strategic technology indicators for future technology selection and new product development.

    –  E-mail: info@selectbio.com

    •  Data for this report was collected on March 7, 2018. –  Annual values for 2018 were extrapolated from 2014-2017 data. –  Four year CAGR’s used data from 2014 and 2017.

    •  This presentation is not management, legal or accounting advice. –  While we believe that the results were accurate at the time of publication, the results are provided without warranty.

    •  © Select Biosciences. 2018. All rights reserved.

    2

  • Exosomes, Extracellular Vesicles & Other Particles: Topic Introduction & the Analysis Process Summary

    3

  • Exosomes, Extracellular Vesicles: Topic Introduction

    •  The focus of this report is on Exosomes, extracellular vesicles and other bodies that may contain information from a cell. –  Our report presents a snapshot of field that we believe is changing focus. –  We frame the data in the context of the current state of Exosomes and ECV’s

    •  To prepare our report, we utilized a four step process. 1.  We IDENTIFIED technical trends in a broadly selected literature database by

    categorizing and segmenting the database into products, product features, materials, processes and methods to form a model.

    2.  We MEASURED each trend progress with unique yardsticks. 3.  We VISUALIZED the trends so that you can see them for yourself. 4.  We PRESENTED our conclusions concisely.

    •  In this report, we analyzed 47,643 publications which en bloc represent the entire body of literature of the Exosome and ECV space.

    •  By casting the technical literature into technology segments, disease-related segments and market-related segments, we believe that we can create an unbiased view across the landscape as a means to identify market segments, trends, and important niches.

    4

    Using keywords to cast technical publications into market focuses, products, product features, materials, processes and methods provides a uniquely accurate picture of how the technology is developing . Such a technological picture also contains unique insights into the structure of the market itself.

  • 5

    Exosomes & EVs are a rapidly expanding area. The Exosome space as represented by our database of 47,643 PubMed titles and abstracts is a rapidly expanding area.. From 2014 to 2017, the CAGR was 9.3%, a significant growth rate even in biotech. We use this value (9.3%) as a benchmark to judge whether a specific segments is growing faster, slower or at the norm for the database.

    Comprehensive Study Database

  • Journals in the Exosome, ECV Database

    6

    The Database contains 3733 journals, and the expected journals top the list. One way to validate the utility of the database is to be sure that it contains journals that cover the Exosome & ECV area. The validation is by experience in the area.

    Rank Journal Number

    of Papers

    Rank Journal Number

    of Papers

    Rank Journal Number

    of Papers

    Rank Journal Number

    of Papers

    1 J. BIOL. CHEM. 1911 26 J. NEUROCHEM. 191 51 EUR. J. IMMUNOL. 127 76 J. CLIN. INVEST. 96 2 PLOS ONE 1169 27 BIOCHEMISTRY 189 52 METH. ENZYMOL. 126 77 FEBS J. 95 3 J. CELL BIOL. 823 28 NAT COMMUN 186 53 SCIENCE 121 78 J. CELL. MOL. MED. 93 4 PROC. NATL. ACAD. SCI. U.S.A. 746 29 CELL TISSUE RES. 185 54 J. THROMB. HAEMOST. 120 79 J. EXP. MED. 93 5 J. CELL. SCI. 702 30 J EXTRACELL VESICLES 180 55 AM. J. PATHOL. 119 80 J. GEN. VIROL. 93 6 MOL. BIOL. CELL 699 31 NATURE 178 56 BIOCONJUG. CHEM. 118 81 BIOPHYS. J. 91 7 TRAFFIC 560 32 THROMB. HAEMOST. 170 57 NUCLEIC ACIDS RES. 118 82 J. LEUKOC. BIOL. 91 8 J. VIROL. 553 33 J. CELL. PHYSIOL. 165 58 MOL. PHARM. 116 83 TRENDS CELL BIOL. 91 9 BIOCHIM. BIOPHYS. ACTA 514 34 CANCER RES. 162 59 J. CELL. BIOCHEM. 115 84 CELL REP 90 10 SCI REP 482 35 CURR. BIOL. 162 60 ACS NANO 111 85 J. HISTOCHEM. CYTOCHEM. 87 11 J. IMMUNOL. 475 36 INFECT. IMMUN. 162 61 CIRC. RES. 111 86 ONCOL. REP. 87 12 BIOCHEM. BIOPHYS. RES. COMMUN. 419 37 PLOS PATHOG. 162 62 NEUROSCIENCE 111 87 SEMIN. CELL DEV. BIOL. 87 13 METHODS MOL. BIOL. 333 38 MOL. CELL. BIOL. 158 63 ENDOCRINOLOGY 110 88 VACCINE 87 14 J. NEUROSCI. 322 39 VIROLOGY 156 64 HUM. MOL. GENET. 110 89 CANCER LETT. 86 15 ONCOTARGET 293 40 NAT. CELL BIOL. 154 65 INT J PHARM 104 90 PROTEOMICS 86 16 BIOCHEM. J. 289 41 AUTOPHAGY 153 66 ONCOGENE 104 91 DEV. BIOL. 85 17 EXP. CELL RES. 283 42 AM. J. PHYSIOL. 149 67 CELL. MOL. LIFE SCI. 103 92 AM. J. PHYSIOL. RENAL PHYSIOL. 84 18 EMBO J. 276 43 INT J MOL SCI 146 68 DEVELOPMENT 101 93 ANTICANCER RES. 84 19 BLOOD 275 44 ADV. EXP. MED. BIOL. 140 69 MOL. CELL 101 94 APOPTOSIS 83 20 J CONTROL RELEASE 260 45 BRAIN RES. 140 70 AM. J. PHYSIOL., CELL PHYSIOL. 100 95 ANN. N. Y. ACAD. SCI. 82 21 BIOMATERIALS 242 46 CELL. MICROBIOL. 140 71 INT. J. CANCER 100 96 J. LIPID RES. 82 22 CELL 223 47 FASEB J. 132 72 ARTERIOSCLER. THROMB. VASC. BIOL. 99 97 BIOL. REPROD. 81 23 EUR. J. CELL BIOL. 213 48 BIOCHEM. SOC. TRANS. 131 73 CURR. OPIN. CELL BIOL. 97 98 TRANSFUSION 81 24 FEBS LETT. 200 49 DEV. CELL 130 74 HEPATOLOGY 97 99 BIOCHEM. PHARMACOL. 78 25 THROMB. RES. 192 50 FRONT IMMUNOL 129 75 J. PHYSIOL. (LOND.) 97 100 KIDNEY INT. 78

    There were 3581 unique journal titles in our database.

  • Regions in the Exosomes & ECV Database

    7

    PubMed provides address information for each author. Addresses can be mined to identify the location (country and region of the world) where the work is being done. Clearly , the US, Asia and Europe are the dominant areas , and each one contributes a similar number of author locations. The same analysis can also be done by country.

    Region Percent of Total

    EUROPE 36.2% USA-COUNTRY 28.8% ASIA 27.1% NORTH AMERICA 3.3% AUSTRALIA 2.6% CENTRAL, SOUTH AMERICA 1.3% AFRICA 0.52% MIDDLE EAST 0.15% CARIBBEAN 0.0378% POLYNESIA, OCEANIA 0.0007%

  • Exosome-Related Terms

    8

    We extracted and counted the terms related to exosomes by year. From that data, we calculated 4-year CAGR’s and plotted the temporal tends. Green indicates that the area is contracting. Red indicates growth. The terms extracellular vesicle, exosome and nanovesicle show strong growth.

    Exosome-Related Terms 4-Yr CAGR CELL-DERIVED MICROPARTICLE -4.62% CIRCULATING MICROPARTICLE 0.00% APOPTOTIC BODY_ APOTOTIC BLEB 2.20% CELL-DERIVED MICROPARTICLE -4.62% CELL-DERIVED VESICLE OR PARTICLE OR MICROPARTICLE 8.93% ECTOSOME_ ECTOSOMES 18.92% ENDOSOME, (S), (AL), (IC, -X -1.67% EXOSOME, (S), (AL), -X 25.28% LYSOSOME 3.20% AUTOPHAGOSOME 10.14% ENDOLYSOSOME -8.34% LIPOSOME 12.91% LYSOSOME 1.97% PHAGOSOME 5.74% EXTRACELLULAR VESICLE 42.35% MULTIVESICULAR BODIES (MVBs) -15.91% SECRETORY VESICLES (FROM GOLGI) 5.38% SYNAPTIC VESICLES -6.60% MICROVESICLE 15.62% NANOVESICLE 22.81% PLATELET_DERIVED MICROPARTICLE 2.20%

  • Trends in Main Exosome-Related Terms

    9

    The 4-year CAGR’s indicated which areas are showing current growth. Temporal plots of authors uses of exosome- related terms area similarly instructive. These are the MAIN terms. Notice that many terms are nearly buried in the noise at the bottom of the char.t

  • Trends in Smaller Exosome-Related Terms

    10

    The 4-year CAGR’s indicated which areas are showing current growth. Temporal plots of authors uses of exosome- related terms area similarly instructive. These are the SMALLER terms. Notice that many terms are nearly buried in the noise at the bottom of the char.t

  • Sample Types in the DB

    11

    Plasma, blood and serum ae the dominant sample types in the Exosome database. Urine (blue) is emerging as is “biofluid” (brown). Many samples types appear to unexplored.

  • Larger Common Technologies

    12

    Common technology methods support developments in Exosomes and ECV’s. CAGR’s range from 6% to 25+%

    fluorescence

    antibody

    western blot

    spectrometry

    mass spec

    ultra-centrifuge centrifuge

    chromatography

  • Smaller Technologies Supporting Exosome & EVs

    13

    Many smaller sized but common technologies are being used in Exosome and ECV developments.

    Precipitation AFM manufacturing

    Density gradient centrifugation

    Notice Scale Change

  • Imaging Methods in Exosomes & EVs

    14

    The general terms in imaging are the most common.

  • Liquid Biopsy: A Newer Assay Term

    15

    While traditional assay methods are growing in the exosome & ECV area,